SpectraCure

0.17 SEK

-0.24 %

Less than 1K followers

SPEC

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-0.24 %

-24.62 %

-0.72 %

-61.26 %

-84.61 %

-66.29 %

-94.32 %

-97.84 %

-73.31 %

SpectraCure operates in the medical technology sector. The company specializes in research and development of medical technology systems used for the treatment of prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internal solid tumors of various types. The largest operations are found in the Nordic market. The company has its headquarters in Lund.

Market cap

68.25M SEK

Turnover

142.69K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19.2

2026

Annual report '25

27.5

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Regulatory press release2/23/2024, 8:30 AM

SpectraCure takes the next step in the work with the new clinical study

Press release1/23/2024, 10:45 AM

A well-accomplished annual audit in accordance with ISO 13485:2016

Regulatory press release12/19/2023, 7:30 AM

Expert group comments on results of ongoing study

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/16/2023, 2:30 PM

SpectraCure has decided to seek approval for a clinical study of primary prostate cancer

Press release10/6/2023, 12:30 PM

SpectraCure strengthens presence among urologists

Regulatory press release6/27/2023, 9:30 AM

SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®

Regulatory press release12/7/2022, 10:00 AM

SpectraCures signs Letter of Intent with Cheplapharm

Regulatory press release8/30/2022, 9:00 AM

SpectraCure: Patent regarding the new generation of treatment systems approved in Europe

Regulatory press release6/7/2022, 12:15 PM

SpectraCure has been approved a grant from EU of € 125,000

Press release5/16/2022, 9:00 AM

A new Board has been installed at SpectraCure

Regulatory press release4/15/2021, 12:00 PM

The Nomination Committee's proposal for election of board members in SpectraCure AB

Regulatory press release3/5/2021, 9:30 AM

SpectraCure: Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer

Regulatory press release9/16/2020, 2:48 PM

SpectraCure: Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!

Regulatory press release6/26/2020, 2:30 PM

SpectraCure raises approximately SEK 140 million through a fully subscribed rights issue

Regulatory press release4/7/2020, 11:00 AM

Patent application enters PCT phase, SpectraCure ensures development and work

Regulatory press release3/12/2020, 12:35 PM

The meeting between SpectraCure and Memorial Sloan Kettering Cancer Center in New York, USA takes place tomorrow, March 13 2020

Regulatory press release1/17/2020, 3:50 PM

A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.

Regulatory press release11/26/2019, 4:56 PM

SpectraCure: Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27

Regulatory press release11/13/2019, 3:20 PM

SpectraCure's main owner subscribes in full for his share

Regulatory press release11/12/2019, 3:00 PM

SpectraCure AB Quarterly Report (1 July to 30 September) 2019

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.